Page last updated: 2024-11-04

2-acetylaminofluorene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-Acetylaminofluorene: A hepatic carcinogen whose mechanism of activation involves N-hydroxylation to the aryl hydroxamic acid followed by enzymatic sulfonation to sulfoxyfluorenylacetamide. It is used to study the carcinogenicity and mutagenicity of aromatic amines. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5897
CHEMBL ID311469
CHEBI ID17356
SCHEMBL ID75140
MeSH IDM0023186

Synonyms (85)

Synonym
CHEMBL311469
CHEBI:17356 ,
2-acetoaminofluorene
azetylaminofluoren
n-acetyl-2-aminofluorene
n-(9h-fluoren-2-yl)acetamide
n-fluoren-2-ylacetamide
2-acetylamino-fluoren
2-(acetylamino)fluorene
wln: l b656 hhj emv1
AAF ,
acetamide, n-9h-fluoren-2-yl-
2-faa
nsc12279
2-acetylaminofluorene
2-fluorenylacetamide
nsc-12279
2-acetaminofluorene
acetamide, n-fluoren-2-yl-
2-aaf
OPREA1_431359
inchi=1/c15h13no/c1-10(17)16-13-6-7-15-12(9-13)8-11-4-2-3-5-14(11)15/h2-7,9h,8h2,1h3,(h,16,17
n-9h-fluoren-2-ylacetamide
2-acetylaminoflourene
2-acetylaminofluorene-3-yl
AFF ,
ai3-52433
brn 2807677
acetoaminofluorene
rcra waste number u005
fluorene, 2-acetamido-
rcra waste no. u005
ccris 1
azetylaminofluoren [german]
2-acetylamino-fluoren [german]
hsdb 4077
2-fluorenil acetamide
einecs 200-188-6
2-aminoacetylfluorene
2-acetylaminfluorene
nsc 12279
53-96-3
2-acetamidofluorene ,
C02778
n-2-fluorenylacetamide
n-(2-fluorenyl)acetamide, >=98% (hplc)
STK386197
A0076
AKOS004006242
NCGC00188968-01
NCGC00188968-02
cas-53-96-3
dtxsid0039227 ,
dtxcid7018
NCGC00258384-01
tox21_200830
9m98qlj2dl ,
unii-9m98qlj2dl
n-(2-fluorenyl)acetamide
FT-0631234
BRD-K63993117-001-01-3
n-2-fluorenylacetamide [mi]
2-acetylaminofluorene [hsdb]
acetylaminofluorene, 2-
c15-h13-n-o
SCHEMBL75140
2-acetylaminofluorine
CZIHNRWJTSTCEX-UHFFFAOYSA-N
CCG-231696
SR-01000394055-1
sr-01000394055
mfcd00001116
Q4382200
Z29958697
BS-16973
2-acetylaminofluorene;2-aaf;2 fluorenylacetamide;fluoren-2-ylacetamide
BCP30181
D82114
SB67003
CS-W014230
PD002504
HY-W013514
GLXC-25238
EN300-7478010
SY067497

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Thus, the overall metabolism of toxic chemicals in hepatocyte cultures seem to be closest to the in vivo situation in the earlier time periods after isolation."( Xenobiotic metabolism and toxicity in primary monolayer cultures of hepatocytes.
Holme, JA, 1985
)
0.27
" Since the dose rate of aromatic amines, like AAF, in feeding studies for tumor formation is about 100 times below that examined in the isolated perfused livers, it is highly unlikely that oxidative stress is generated by metabolites able to undergo redox cycling and that reactive oxygen contributes to acute toxic effects."( Cytotoxicity of aromatic amines in rat liver and oxidative stress.
Hillesheim, W; Jaeschke, H; Neumann, HG, 1995
)
0.29
"Isolated perfused livers from male Wistar rats were used to study acute and chronic toxic effects of carcinogenic aromatic amines."( Acute and chronic toxicity of aromatic amines studied in the isolated perfused rat liver.
Ambs, S; Neumann, HG, 1996
)
0.29
" The ability of butylated hydroxyanisole (BHA) to attenuate the toxic effect of 2-AAF was also examined."( Chemoprevention of 2-acetylaminofluorene-induced hepatotoxicity and lipid peroxidation in rats by kolaviron--a Garcinia kola seed extract.
Agboola, AO; Emerole, GO; Farombi, EO; Nwankwo, JO; Tahnteng, JG, 2000
)
0.64
" Uridine uptake was always inhibited at lower concentrations than those required in the neutral red assay, suggesting that the uridine uptake assay is a more sensitive indicator of toxic action than the neutral red inclusion."( Uridine uptake inhibition as a cytotoxicity test for a human hepatoma cell line (HepG2 cells): comparison with the neutral red assay.
Chagnon, M; Lhuguenot, J; Philippe, M; Valentin, I, 2001
)
0.31
" Thus, glucuronidation may contribute to the elimination of CYP-mediated reactive intermediate metabolites, preventing a toxic event."( The contribution of UDP-glucuronosyltransferase 1A9 on CYP1A2-mediated genotoxicity by aromatic and heterocyclic amines.
Famourzadeh, M; Guengerich, FP; Nguyen, N; Oda, Y; Strassburg, CP; Tukey, RH; Yueh, MF, 2001
)
0.31
" Therefore, ciprofloxacin is considered to be safe for therapeutic use."( Ciprofloxacin: in vivo genotoxicity studies.
Ahr, HJ; Brendler-Schwaab, SY; Herbold, BA, 2001
)
0.31
" Our results showed a resistance to the toxic effects of EA since viability and cellular integrity values were significantly higher than control."( Hepatocytes isolated from preneoplastic rat livers are resistant to ethacrynic acid cytotoxicity.
Alvarez, Mde L; Carnovale, C; Carrillo, MC; Francés, D; Parody, JP; Quiroga, A; Ronco, MT, 2007
)
0.34
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36

Pharmacokinetics

ExcerptReferenceRelevance
" To determine if the absorption, distribution, metabolism, or elimination of 2-AAF was altered by the age of the animals, diet, or 2-AAF treatment, pharmacokinetic studies were conducted on young (11 weeks) and old (78 weeks) BALB/c mice that had been fed one of four diets containing 4 or 24% fat and 12 or 24% protein."( Dietary and age influence on the pharmacokinetic parameters of 2-acetylaminofluorene in BALB/c mice.
Norvell, MJ; Young, JF, 1984
)
0.51

Compound-Compound Interactions

ExcerptReferenceRelevance
"025% 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) for two weeks combined with partial hepatectomy at the end of the first week and followed by long-term treatment with phenobarbital (PB) or 3'-methyl-4-dimethylaminoazobenzene (3'-Me-DAB) from week 3 to week 86 resulted in dose-dependent development of liver and thyroid neoplastic and preneoplastic lesions."( Dose-dependent induction of liver and thyroid neoplastic lesions by short-term administration of 2-amino-3-methylimidazo[4,5-f]quinoline combined with partial hepatectomy followed by phenobarbital or low dose 3'-methyl-4-dimethylaminoazobenzene promotion.
Asamoto, M; Inoue, T; Ito, N; Nagao, M; Ogiso, T; Tsuda, H, 1988
)
0.27

Bioavailability

ExcerptReferenceRelevance
"5 microM, the rate of absorption decreases over a 20 min period, which also indicates some form of specific interaction between 2-acetylaminofluorene and the intestinal mucosa."( Absorption of 2-acetylaminofluorene in the guinea-pig colon.
Dougherty, MA; Nahrwold, DL; Rose, RC; Weimer, GR, 1979
)
0.83
" Swelling was determined as maximal rate of absorption decrease at 540 nm (delta A/delta t)."( Mitochondrial permeability transition is altered in early stages of carcinogenesis of 2-acetylaminofluorene.
Bitsch, A; Klöhn, PC; Neumann, HG, 1998
)
0.52

Dosage Studied

The carcinogenic dose-response relationship for genotoxic chemicals (such as 2-acetylaminofluorene) was also due in part to increased cell proliferation.

ExcerptRelevanceReference
"In order to investigate the relationship between mutation and carcinogenesis in vivo, a method has been developed in which somatic mutation can be studied in specific organs of Chinese hamsters after acute dosing with chemical carcinogens."( Organotropic mutagenesis in tissues of Chinese hamsters induced by chemical carcinogens.
Dean, BJ; Hodson-Walker, G; Senner, KR, 1979
)
0.26
" This reaction shows an unequivocal dose-response relationship."( Stimulation of thymocytes in vitro by serum of 2-acetylaminofluorene (AAF)-treated rats.
Bräuer, R; Danz, M; Urban, H; Waldmann, G, 1979
)
0.52
" Feeding the chemical at levels of 8 to 86 ppm results in a dose-response related urinary bladder hyperplasia and, after 9 to 12 months, in bladder neoplasia at the higher dose levels."( Dose-response hyperplasia and neoplasia from feeding N-2-fluorenylacetamide (2-FAA) to BALB/c mice for varying time intervals.
Farmer, J; Frith, C; Haley, TJ; Jaques, WE; Schieferstein, G; Sprowls, RW, 1976
)
0.26
" The data indicate that at least in hepatocellular tumours of the C57Bl/10J strain and using chronic dosing regimes the ras genes do not represent markers for in vivo genotoxic activity."( Point mutation analysis of ras genes in spontaneous and chemically induced C57Bl/10J mouse liver tumours.
Hardaker, KJ; Lord, PG; Loughlin, JM; Marsden, AM; Orton, TC, 1992
)
0.28
" It has previously been shown that a multiple dosing regimen with AFB1, started after 3 weeks of CMD diet, enhances tumor incidence."( Liver DNA adducts in methyl-deficient rats administered a single dose of aflatoxin B1.
Laver, GW; McMullen, E; Mehta, R; Stapley, R, 1992
)
0.28
" At nodular and post-nodular stages biliary excretion of radioactive metabolites was decreased, although hepatic content of radioactivity was similar to controls not dosed with AAF."( Protein binding, nuclear translocation and biliary secretion of metabolites of 3'-methyl-N,N-dimethyl-4-aminoazobenzene during hepatocarcinogenesis in rats.
Bhargava, MM; Levine, WG; Srinivasan, K, 1991
)
0.28
" Hence, the levels of statistical significance obtained for dose-response trends and comparisons of treated and control groups were similar using 48 animals per dose groups with B6C3 mice, or combinations of 24 animals per dose from 2 genotypes, or 12 animals per dose from the 4 hybrid genotypes."( Bladder and liver tumorigenesis induced by 2-acetylaminofluorene in different F1 mouse hybrids: variation within genotypes and effects of using more than one genotype on risk assessment.
Blackwell, BN; Gaylor, DW; Moore, GE; Wolff, GL, 1991
)
0.54
"A factorial experimental design was used within this study to evaluate the influence of multiple metabolic activation system concentrations on the dose-response exhibited by promutagens (indirect-acting mutagens) in the Salmonella spiral and plate assays."( Evaluating the relationship of metabolic activation system concentrations and chemical dose concentrations for the Salmonella spiral and plate assays.
Allison, JC; Claxton, LD; Creason, J; Houk, VS, 1991
)
0.28
"The two-stage clonal expansion model for a single, less-than-lifetime period of dosing is formulated and applied to the liver and bladder tumor data from the ED01 study."( Two-stage and Weibull models for carcinogenesis applied to the ED01 discontinued dosing data.
Felton, RP; Kodell, RL, 1991
)
0.28
" Each group consisted of 96 mice, except the groups of females dosed at 0 and 150 ppm, which consisted of 120 and 72 mice, respectively."( Increased incidence of spontaneous and 2-acetylaminofluorene-induced liver and bladder tumors in B6C3F1 mice fed AIN-76A diet versus NIH-07 diet.
Bucci, TJ; Fullerton, FR; Greenman, DL; McCarty, CC, 1991
)
0.55
"In contrast to earlier studies conducted at lower dose levels, 2AAF is shown to induce a positive UDS response in the liver of mice dosed orally at dose levels between 500 and 1000 mg/kg."( Relative sensitivity of 32P-postlabelling of DNA and the autoradiographic UDS assay in the liver of mice exposed to 2-acetylaminofluorene (2AAF).
Ashby, J; Gallagher, JE; Lefevre, PA; Lewtas, J; Shank, T, 1991
)
0.49
" The carcinogenic dose-response relationship for genotoxic chemicals (such as 2-acetylaminofluorene) was also due in part to increased cell proliferation."( Cell proliferation in carcinogenesis.
Cohen, SM; Ellwein, LB, 1990
)
0.51
" Moreover, maximal mutation frequency at the Na+/K(+)-ATPase gene locus (ouar mutation) was attained within 30 or 40 min of exposure, dependent on dosage of N-NO-AAF."( Induction of ouabain-resistance mutation and cycle-dependent transformation of C3H/10T1/2 cells by N-nitroso-2-acetylaminofluorene.
Kuo, ML; Lin, JK, 1990
)
0.49
" By using a biologically based model of two-event carcinogenesis accounting explicitly for both genotoxic and nongenotoxic proliferative effects at the cellular level, we provide a unifying explanation for the apparently disparate dose-response results observed in the urinary bladder and liver."( Proliferative and genotoxic cellular effects in 2-acetylaminofluorene bladder and liver carcinogenesis: biological modeling of the ED01 study.
Cohen, SM; Ellwein, LB, 1990
)
0.53
" However, sodium saccharin dosing did not result in an increased incidence of tumors in either the bladder or liver and is therefore not considered to be a promoter of carcinogenesis at these sites in the mouse."( The effect of lifetime sodium saccharin dosing on mice initiated with the carcinogen 2-acetylaminofluorene.
Dooley, KL; Frederick, CB; Kadlubar, FF; Kodell, RL; Sheldon, WG, 1989
)
0.5
" However, a gene dose-response relationship was observed in the same animals for cytosolic acetyl coenzyme A-dependent 2-aminofluorene N-acetyltransferase activity."( The role of acetylator genotype on hepatic and extrahepatic acetylation, deacetylation, and sulfation of 2-aminofluorene, 2-acetylaminofluorene, and N-hydroxy-2-acetylaminofluorene in the inbred hamster.
Ferguson, RJ; Hein, DW; Kirlin, WG; Ogolla, F; Thompson, LK; Trinidad, A,
)
0.34
" There are no molecular dosimetry studies on the DNA adducts of 2-AAF, even though such a unique data base exists for the dose-response relationship of mouse liver tumors."( DNA damage and repair in mouse liver.
Fennell, TR; Swenberg, JA, 1987
)
0.27
" In order to compare DNA-incising capacities of the various cell strains after UV irradiation with those after treatment with (Ac)2ONFln, dose-response experiments including up to 8 dose levels were performed."( Comparison of DNA-incising capacities in fibroblast strains from the Mannheim XP collection after treatment with N-acetoxy-2-acetylaminofluorene and UV light.
Popanda, O; Thielmann, HW, 1988
)
0.48
" There were substantial differences in the diagnoses of both tumor types by the pathologists, but the implications for detection of a dose-response relationship are important only for liver carcinomas."( Analysis of agreement among findings of pathologists in ED01 experiment.
Amato, DA; Lagakos, SW, 1988
)
0.27
" Male CD-1 mice, 50-100 days old, were dosed orally with N-nitrosodimethylamine (NDMA), trichloroethylene (TCE), 2-acetylaminofluorene (2-AAF), 4-acetylaminofluorene (4-AAF), phenobarbital (PB) or a vehicle."( The in vivo-in vitro hepatocyte assay for assessing DNA repair and DNA replication: studies in the CD-1 mouse.
Doolittle, DJ; Muller, G; Scribner, HE, 1987
)
0.48
" The dose-response curve obtained when the number of autoradiographic grains developed over the nuclei was plotted as a function of the concentration of N-AcO-AAF used to treat the cells, indicated that the extent of specific antibody-binding is determined by the amount of adducts in the cells."( Detection of DNA adducts in N-acetoxy-2-acetylaminofluorene-treated human fibroblasts by means of immunofluorescence microscopy and quantitative immunoautoradiography.
Baan, RA; Lohman, PH; Muysken-Schoen, MA, 1985
)
0.54
" Dose-response curves for mutagenicity of quercetin with or without AAF (5 micrograms/plate) were examined."( The effect of quercetin on the mutagenicity of 2-acetylaminofluorene and benzo[alpha]pyrene in Salmonella typhimurium strains.
Fukui, S; Hirai, K; Hirayama, T; Nohara, M; Ogawa, S; Tokuda, M, 1985
)
0.53
"Oral dosing of between 5-30 mg/kg of cyclophosphamide (CP) to Alderley Park rats induced micronuclei in the bone marrow between 12 and 36 h after dosing, but failed to induce unscheduled DNA synthesis (UDS) in the liver at similar dose levels and treatment periods."( Concomitant observations of UDS in the liver and micronuclei in the bone marrow of rats exposed to cyclophosphamide or 2-acetylaminofluorene.
Ashby, J; Beije, B,
)
0.34
" A number of mathematical dose-response models have been proposed for extrapolation purposes; we have shown how similar they can appear to one another in the range of observable response rates, yet how different they become at lower, unobservable response rates, the region of primary interest."( Statistical aspects of the estimation of human risks.
Brown, CC, 1985
)
0.27
" Differences in dose-response curves for certain mutagens using liver and intestinal microsomes are discussed in relation to variation in metabolism of promutagens."( Characterization of a microsomal fraction from rat small intestine for metabolic activation of some promutagens.
Combes, RD; Walters, JM, 1985
)
0.27
"One element of the ED01 Study contained a group of animals that were dosed with 2-acetylaminofluorene for 9, 12, 15, 18, or 24 mo and then sacrificed at 18 or 24 mo."( Influence of total dose and dose rate in carcinogenicity studies.
Gaylor, DW; Littlefield, NA, 1985
)
0.5
" The dose response over the entire dosage range gave the impression of a "threshold" type response below the mid-doses."( Urinary bladder neoplasms induced in BALB/c female mice with low doses of 2-acetylaminofluorene.
Frith, CH; Gaylor, DW; Greenman, DL,
)
0.36
" N-OH-AAF dependent ODC induction displayed an almost linear dose-response in the dose range up to 94."( Induction of ornithine decarboxylase and augmentation of tyrosine aminotransferase activity by N-hydroxy-2-acetylaminofluorene and 2-acetylaminofluorene in rat liver. Influence of sex, retinylacetate, indomethacin, and pentachlorophenol.
Bakker, O; Bisschop, A; Meerman, JH; Stavenuiter, JF; van der Heijden, CA; van Wijk, R, 1984
)
0.48
" Under standardized conditions, the assay yielded a dose-response relationship for transformation to anchorage independence over the concentration range of 0 to 10 microM N-acetoxy-2-acetylaminofluorene."( Characterization of a quantitative assay for the in vitro transformation of normal human diploid fibroblasts to anchorage independence by chemical carcinogens.
Little, JB; Zimmerman, RJ, 1983
)
0.46
" Metabolic activation was provided by ferret or rat hepatic S-9 fractions at 5 levels for each chemical, and optimal S-9 levels as well as dose-response curves were obtained."( In vitro activation of the promutagens 2-acetamidofluorene, cyclophosphamide and 7,12-dimethylbenzanthracene by constitutive ferret and rat hepatic S-9 fractions.
Babish, JG; Frederick, KA, 1984
)
0.27
" The dosing was continuous until time of death for most of the mice."( Multistage prediction of cancer in serially dosed animals with application to the ED01 study.
Brown, KG; Hoel, DG,
)
0.13
"The relationships between the shelf level at which mice were housed and body weight and food consumption/wastage were examined by analyzing data obtained from the first 9 months of a carcinogenic dose-response study carried out in 24,192 female BALB/c mice using 2-acetylaminofluorene (2-AAF) as the carcinogen."( Relationship of mouse body weight and food consumption/wastage to cage shelf level.
Bryant, P; Greenman, DL; Kodell, RL; Sheldon, W, 1983
)
0.45
" administration of AAF to F-344 rats produced log-linear dose-response curves for epoxide hydrolase elevation, measured with either benzo[a]pyrene-4,5-oxide or styrene oxide substrate."( Elevation of hepatic microsomal epoxide hydrolase activity by 2-acetylaminofluorene: strain and species differences.
Dent, JG; Graichen, ME, 1984
)
0.51
" Blood, urine, and feces samples were obtained over a 31-hr period after dosing with 500 ppm 2-[14C]AAF (10 microCi/mouse)."( Dietary and age influence on the pharmacokinetic parameters of 2-acetylaminofluorene in BALB/c mice.
Norvell, MJ; Young, JF, 1984
)
0.51
" While a dose-dependent increase in SCE was obtained for both procarcinogens at each age, the mean SCE frequency was significantly higher in the 6-day embryos for each dosage given."( Differential induction of sister chromatid exchanges by indirect-acting mutagen-carcinogens at early and late stages of embryonic development.
Bloom, SE; Todd, LA, 1980
)
0.26
"Using the Solt and Farber model (Nature, 263 (1976) 701), dose-response relationships between initiating agents and the induction of hyperplastic nodules in rat liver were investigated."( Dose responses of five hepatocarcinogens for the initiation of rat hepatocarcinogenesis.
Imaida, K; Ito, N; Shirai, T; Takano, T; Tatematsu, M, 1981
)
0.26
" This reaction shows a clear dose-response relationship."( Thymocyte stimulating activity of the serum of rats in the early phase after 2-acetylaminofluorene (AAF)-treatment.
Bräuer, R; Danz, M; Urban, H; Waldmann, G, 1980
)
0.49
" It is pointed out that the problems of statistical analysis that arise when dosed animals live longer than controls (as occurred in the ED01 study) raise questions about the design of lifetime feeding studies in general."( Re-examination of the ED01 study - adjusting for time on study.
,
)
0.13
" The presence of HU during chemical treatment and throughout this 18 h of incubation with [3H]dThd did not influence the dose-response curves obtained with UV, MMS, NA-AAF and BaP but it increased the input dose of MNNG, MMC, DMN and AFB1 required to give peak repair incorporation."( Chemical carcinogen induction of DNA-repair synthesis in human peripheral blood monocytes.
Igel, HJ; Kropko, ML; Lake, RS; McLachlan, S; Pezzutti, MR; Shoemaker, RH, 1980
)
0.26
" Four hours after dosing the animals were sacrificed and hepatic DNA was isolated."( Role of sulfation in the formation of DNA adducts from N-hydroxy-2-acetylaminofluorene in rat liver in vivo. Inhibition of N-acetylated aminofluorene adduct formation by pentachlorophenol.
Beland, FA; Meerman, JH; Mulder, GJ, 1981
)
0.5
" The study design consisted of sacrifice intervals, life span, and discontinued dosing groups."( Effects of dose and time in a long-term, low-dose carcinogenic study.
Farmer, JH; Gaylor, DW; Littlefield, NA; Sheldon, WG, 1980
)
0.26
" Although a pronounced dose-response for time-to-tumor was expressed for both bladder and liver neoplasms, the time required for death from either neoplasm following its appearance was not dose-related."( Estimation of distributions of time to appearance of tumor and time to death from tumor after appearance in mice fed 2-acetylaminofluorene.
Farmer, JH; Frith, CH; Greenman, DL; Kodell, RL, 1980
)
0.47
" The linear dose-response relationship of tissue binding correlated well with the previously reported linear dose response curve for liver tumors but did not correlated with the reported non-linear dose response curve for bladder tumors."( Tissue binding of 2-acetylaminofluorene in BAlB/c and C57Bl/6 mice during chronic oral administration.
Jackson, CD; Shellenberger, TE; Weis, C, 1980
)
0.59
"Double dosing and single sampling seems to be the simplest and most reliable method for detecting clastogens in the mouse peripheral blood micronucleus test."( An optimal, generalized sampling time of 30 +/- 6 h after double dosing in the mouse peripheral blood micronucleus test.
Higashikuni, N; Sutou, S, 1995
)
0.29
" Cell proliferation can affect the dose-response curve for genotoxic carcinogens and is the basis for carcinogenicity by nongenotoxic agents."( Role of cell proliferation in regenerative and neoplastic disease.
Cohen, SM, 1995
)
0.29
" dosing with 100 mg/kg CPA once a week for 6 successive weeks induced, as compared to controls, a significant increase in the number and area of gamma-glutamyltranspeptidase-positive foci."( Induction of micronuclei and initiation of enzyme-altered foci in the liver of female rats treated with cyproterone acetate, chlormadinone acetate, or megestrol acetate.
Allavena, A; Brambilla Campart, G; Brambilla, G; Ghia, M; Martelli, A; Mereto, E, 1996
)
0.29
" This is commonly thought of as a dose-response relationship which is linear at low dose."( Thresholds in chemical carcinogenesis.
Auton, TR; Purchase, IF, 1995
)
0.29
" In this article, we consider statistical tests for increasing trend in mutant frequency with increasing dose, along with statistical models that may be used to describe the observed dose-response relationships."( Statistical analysis of the lacI transgenic mouse mutagenicity assay.
Fung, KY; Krewski, D; Lutz, WK; Shephard, S; Zhu, Y, 1997
)
0.3
" Chronic dosing experiments in animal models are of interest for human risk assessment because human exposure is typically intermittent, involving repeated exposures."( Aromatic amine DNA adduct formation in chronically-exposed mice: considerations for human comparison.
Beland, FA; Poirier, MC, 1997
)
0.3
" In addition, urinary radiotracer excretion was reduced by 96% in specific-antibody dosed mice, indicating reduced gastrointestinal absorption of 125I-pHP-AAF."( Peroral administration of specific antibody enhances carcinogen excretion.
Rasmussen, MV; Silbart, LK, 1998
)
0.3
" In contrast, both DMN 2-4 hr after dosing and 2-AAF 12-16 hr after dosing produced significant increases in UDS assessed as the net nuclear grain count."( Lack of effect of coumarin on unscheduled DNA synthesis in the in vivo rat hepatocyte DNA repair assay.
Edwards, AJ; Lake, BG; Price, RJ; Renwick, AB, 2000
)
0.31
" Furfural was dosed by gavage at levels of 0 (control), 50, 175 and 320 mg/kg to male and female mice and 0, 5, 16."( Lack of effect of furfural on unscheduled DNA synthesis in the in vivo rat and mouse hepatocyte DNA repair assays and in precision-cut human liver slices.
Adams, TB; Beamand, JA; Edwards, AJ; Lake, BG; Phillips, BJ; Price, RJ; Renwick, AB, 2001
)
0.31
" The chemicals were found to differ characteristically in their potency and dose-response relationship to induce FAH when given alone or when administered following initiation with diethylnitrosamine."( Prevalidation of a rat liver foci bioassay (RLFB) based on results from 1600 rats: a study report.
Bannasch, P; Brendler-Schwaab, S; Deml, E; Enzmann, H; Haertel, T; Ittrich, C; Kopp-Schneider, A; Küttler, K; Mellert, W; Mönnikes, O; Oesterle, D; Schladt, L; Schwarz, M,
)
0.13
" The slopes of the dose-response curves for bladder neoplasms from 17 months through 33 months were consistently very steep, while those for liver neoplasms increased from a shallow slope at 18 months to a steep slope at 33 months."( Thresholds of carcinogenicity in the ED01 study.
Waddell, WJ, 2003
)
0.32
"Comparisons on a linear and the Rozman logarithmic scale for dosage versus carcinogenicity in rodents are presented for methyl eugenol (ME), nitrosodiethylamine (NDEA), ethyl carbamate (EC) and 2-acetylaminofluorene (AAF)."( Comparisons of thresholds for carcinogenicity on linear and logarithmic dosage scales.
Waddell, WJ, 2005
)
0.52
"5 ppm dosage in drinking water in a defined model of a two-stage experimental rat hepatocarcinogenesis."( Vanadium inhibits the development of 2-acetylaminofluorene-induced premalignant phenotype in a two-stage chemical rat hepatocarcinogenesis model.
Chakraborty, T; Chatterjee, A; Chatterjee, M; Dhachinamoorthi, D; Saralaya, MG, 2006
)
0.61
" This study was undertaken to help elucidate dose-response changes in gene expression (transcriptome) in the liver of rats in response to administration of known genotoxic or nongenotoxic liver carcinogens."( Gene expression dose-response of liver with a genotoxic and nongenotoxic carcinogen.
Gollapudi, BB; Kan, HL; Seidel, SD; Sparrow, BR; Stott, WT,
)
0.13
" The animals were dosed for seven consecutive days with Ho, Ga and Bi as dietary supplements."( Protection against 2- acetyl aminofluorene-induced toxicity in mice by garlic (Allium sativum), bitter kola (Garcina kola seed) and honey.
Adetutu, A; Odunola, OA; Ola-Davis, O; Olorunnisola, OS, 2005
)
0.33
" Examples are shown, illustrating that the current practice of labeling dose-response curves for carcinogenesis as supralinear, linear or sublinear, is meaningless unless the dose-response scales are defined."( Critique of dose response in carcinogenesis.
Waddell, WJ, 2006
)
0.33
" The rats were observed daily and body weights were taken before initial dosing and at weekly intervals thereafter."( Inhibition by dietary hydroquinone of acetylaminofluorene induction of initiation of rat liver carcinogenesis.
Duan, JD; Iatropoulos, MJ; Jeffrey, AM; Williams, GM, 2007
)
0.34
"Within the scope of the Rat Liver Foci Bioassay the model carcinogens N-nitrosomorpholine (NNM), 2-acetylaminoflouren (2-AAF), phenobarbital (PB), and clofibrate (CF) were analyzed concerning their potency and dose-response relationship to induce foci of altered hepatocytes (FAHs), which are known to be precursor lesions of liver adenoma and carcinoma."( Comparison of mode of action of four hepatocarcinogens: a model-based approach.
Bannasch, P; Groos, J; Kopp-Schneider, A; Schwarz, M, 2007
)
0.34
" Similarly, the level of AAF-DNA adducts formed in cultured male rat hepatocytes dosed with AAF was about twofold greater than in female rat hepatocytes."( Sex differences in DNA damage produced by the carcinogen 2-acetylaminofluorene in cultured human hepatocytes compared to rat liver and cultured rat hepatocytes.
Duan, JD; Iatropoulos, MJ; Perrone, CE; Williams, GM, 2016
)
0.68
" Male rats were orally administered a single dose of each test compound, and both the RBC Pig-a and PIGRET assays were performed using flow cytometry to measure the Pig-a mutant frequency (MF) before and after dosing on Days 8, 15 and 29."( Results of rat Pig-a/PIGRET assay with a single dose regimen of 1,3-propane sultone and 2-acetyl aminofluorene.
Hamada, S; Harada, H; Ishii, N; Shigano, M; Takasawa, H; Takashima, R, 2016
)
0.43
" However, a dose-response function (DRF), informed by various levels of information including apical health response, can represent a template for convergent top-down, bottom-up analysis."( A general dose-response relationship for chronic chemical and other health stressors and mixtures based on an emergent illness severity model.
Chiu, WA; Englehardt, JD, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
antimitoticAny compound that inhibits cell division (mitosis).
carcinogenic agentA role played by a chemical compound which is known to induce a process of carcinogenesis by corrupting normal cellular pathways, leading to the acquistion of tumoral capabilities.
mutagenAn agent that increases the frequency of mutations above the normal background level, usually by interacting directly with DNA and causing it damage, including base substitution.
epitopeThe biological role played by a material entity when bound by a receptor of the adaptive immune system. Specific site on an antigen to which an antibody binds.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
2-acetamidofluorenesAn ortho-fused polycyclic arene, or derivative thereof, that consists of 9H-fluorene bearing an acetamido substituent at position 2.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (31)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency28.71930.007215.758889.3584AID1224835
RAR-related orphan receptor gammaMus musculus (house mouse)Potency17.05670.006038.004119,952.5996AID1159521; AID1159523
AR proteinHomo sapiens (human)Potency26.60580.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743042; AID743054; AID743063
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency35.13290.000657.913322,387.1992AID1259377; AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency27.23720.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency7.81340.000417.946075.1148AID1346795
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency39.51950.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency5.32210.003041.611522,387.1992AID1159552; AID1159553; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency8.61330.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency24.70820.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency6.19240.000229.305416,493.5996AID1259244; AID1259248; AID1259383; AID743079; AID743080; AID743091
aryl hydrocarbon receptorHomo sapiens (human)Potency45.10800.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency4.39380.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency48.39760.001628.015177.1139AID1224843; AID1224895
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency55.822819.739145.978464.9432AID1159509
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency19.62640.000323.4451159.6830AID743065
histone deacetylase 9 isoform 3Homo sapiens (human)Potency33.68630.037617.082361.1927AID1259364; AID1259388
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency27.72310.000627.21521,122.0200AID743202; AID743219
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency4.92990.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency4.92990.001551.739315,848.9004AID1259244
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency40.27920.011917.942071.5630AID651632; AID720516
Ataxin-2Homo sapiens (human)Potency34.90130.011912.222168.7989AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)IC50 (µMol)2.14300.00011.00768.7800AID625218
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)Ki1.12200.00000.887110.0000AID625218
Cytochrome P450 1A2Homo sapiens (human)IC50 (µMol)0.01600.00011.774010.0000AID625245
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)IC50 (µMol)8.59500.00041.877310.0000AID625207
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)Ki8.52400.00322.28879.3160AID625207
Alpha-2A adrenergic receptorHomo sapiens (human)IC50 (µMol)21.06100.00001.44217.3470AID625201
Alpha-2A adrenergic receptorHomo sapiens (human)Ki7.89800.00010.807410.0000AID625201
Amine oxidase [flavin-containing] AHomo sapiens (human)IC50 (µMol)0.05900.00002.37899.7700AID625150
Sodium-dependent noradrenaline transporter Homo sapiens (human)IC50 (µMol)8.59500.00081.541620.0000AID625207
Sodium-dependent noradrenaline transporter Homo sapiens (human)Ki8.52400.00031.465610.0000AID625207
5-hydroxytryptamine receptor 2CHomo sapiens (human)IC50 (µMol)2.14300.00011.03029.0000AID625218
5-hydroxytryptamine receptor 2CHomo sapiens (human)Ki1.12200.00010.954910.0000AID625218
Sodium-dependent serotonin transporterHomo sapiens (human)IC50 (µMol)6.05300.00010.86458.7096AID625222
Sodium-dependent serotonin transporterHomo sapiens (human)Ki3.21600.00000.70488.1930AID625222
5-hydroxytryptamine receptor 2BHomo sapiens (human)IC50 (µMol)3.17000.00011.18738.9125AID625217
5-hydroxytryptamine receptor 2BHomo sapiens (human)Ki2.01700.00030.769310.0000AID625217
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (163)

Processvia Protein(s)Taxonomy
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
positive regulation of cytokine productionAlpha-2A adrenergic receptorHomo sapiens (human)
DNA replicationAlpha-2A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
Ras protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
Rho protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2A adrenergic receptorHomo sapiens (human)
actin cytoskeleton organizationAlpha-2A adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell migrationAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
cellular response to hormone stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2A adrenergic receptorHomo sapiens (human)
vasodilationAlpha-2A adrenergic receptorHomo sapiens (human)
glucose homeostasisAlpha-2A adrenergic receptorHomo sapiens (human)
fear responseAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of potassium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAP kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion-dependent exocytosisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2A adrenergic receptorHomo sapiens (human)
intestinal absorptionAlpha-2A adrenergic receptorHomo sapiens (human)
thermoceptionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of lipid catabolic processAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of membrane protein ectodomain proteolysisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of uterine smooth muscle contractionAlpha-2A adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
phospholipase C-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of wound healingAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transmembrane transporter activityAlpha-2A adrenergic receptorHomo sapiens (human)
biogenic amine metabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
positive regulation of signal transductionAmine oxidase [flavin-containing] AHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
monoamine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent noradrenaline transporter Homo sapiens (human)
chemical synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent noradrenaline transporter Homo sapiens (human)
response to painSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent noradrenaline transporter Homo sapiens (human)
neuron cellular homeostasisSodium-dependent noradrenaline transporter Homo sapiens (human)
amino acid transportSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent noradrenaline transporter Homo sapiens (human)
behavioral fear response5-hydroxytryptamine receptor 2CHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
locomotory behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
feeding behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2CHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of nervous system process5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of appetite5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of corticotropin-releasing hormone secretion5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of calcium-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2CHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2CHomo sapiens (human)
monoamine transportSodium-dependent serotonin transporterHomo sapiens (human)
response to hypoxiaSodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transportSodium-dependent serotonin transporterHomo sapiens (human)
response to nutrientSodium-dependent serotonin transporterHomo sapiens (human)
memorySodium-dependent serotonin transporterHomo sapiens (human)
circadian rhythmSodium-dependent serotonin transporterHomo sapiens (human)
response to xenobiotic stimulusSodium-dependent serotonin transporterHomo sapiens (human)
response to toxic substanceSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of gene expressionSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of serotonin secretionSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of cerebellar granule cell precursor proliferationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of synaptic transmission, dopaminergicSodium-dependent serotonin transporterHomo sapiens (human)
response to estradiolSodium-dependent serotonin transporterHomo sapiens (human)
social behaviorSodium-dependent serotonin transporterHomo sapiens (human)
vasoconstrictionSodium-dependent serotonin transporterHomo sapiens (human)
sperm ejaculationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of neuron differentiationSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of cell cycleSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of organ growthSodium-dependent serotonin transporterHomo sapiens (human)
behavioral response to cocaineSodium-dependent serotonin transporterHomo sapiens (human)
enteric nervous system developmentSodium-dependent serotonin transporterHomo sapiens (human)
brain morphogenesisSodium-dependent serotonin transporterHomo sapiens (human)
serotonin uptakeSodium-dependent serotonin transporterHomo sapiens (human)
membrane depolarizationSodium-dependent serotonin transporterHomo sapiens (human)
platelet aggregationSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to retinoic acidSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to cGMPSodium-dependent serotonin transporterHomo sapiens (human)
regulation of thalamus sizeSodium-dependent serotonin transporterHomo sapiens (human)
conditioned place preferenceSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion transmembrane transportSodium-dependent serotonin transporterHomo sapiens (human)
amino acid transportSodium-dependent serotonin transporterHomo sapiens (human)
neural crest cell migration5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cytokine production5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of endothelial cell proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor internalization5-hydroxytryptamine receptor 2BHomo sapiens (human)
heart morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
cardiac muscle hypertrophy5-hydroxytryptamine receptor 2BHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
neural crest cell differentiation5-hydroxytryptamine receptor 2BHomo sapiens (human)
intestine smooth muscle contraction5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphorylation5-hydroxytryptamine receptor 2BHomo sapiens (human)
calcium-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 2BHomo sapiens (human)
negative regulation of apoptotic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of MAP kinase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
embryonic morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of nitric-oxide synthase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell division5-hydroxytryptamine receptor 2BHomo sapiens (human)
ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cellular response to temperature stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2BHomo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (62)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein kinase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-1B adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-2C adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
thioesterase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
heterotrimeric G-protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
norepinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
actin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
protein bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
alpha-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
metal ion bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
beta-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
integrin bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoatomic cation channel activitySodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
serotonin:sodium:chloride symporter activitySodium-dependent serotonin transporterHomo sapiens (human)
protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
antiporter activitySodium-dependent serotonin transporterHomo sapiens (human)
syntaxin-1 bindingSodium-dependent serotonin transporterHomo sapiens (human)
cocaine bindingSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion bindingSodium-dependent serotonin transporterHomo sapiens (human)
identical protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
nitric-oxide synthase bindingSodium-dependent serotonin transporterHomo sapiens (human)
actin filament bindingSodium-dependent serotonin transporterHomo sapiens (human)
serotonin bindingSodium-dependent serotonin transporterHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
G-protein alpha-subunit binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
GTPase activator activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (39)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
cytoplasmAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
basolateral plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
neuronal cell bodyAlpha-2A adrenergic receptorHomo sapiens (human)
axon terminusAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic active zone membraneAlpha-2A adrenergic receptorHomo sapiens (human)
dopaminergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
postsynaptic density membraneAlpha-2A adrenergic receptorHomo sapiens (human)
glutamatergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
GABA-ergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
receptor complexAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] AHomo sapiens (human)
cytosolAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
cell surfaceSodium-dependent noradrenaline transporter Homo sapiens (human)
membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
presynaptic membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
axonSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
focal adhesionSodium-dependent serotonin transporterHomo sapiens (human)
endosome membraneSodium-dependent serotonin transporterHomo sapiens (human)
endomembrane systemSodium-dependent serotonin transporterHomo sapiens (human)
presynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
membrane raftSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
postsynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
serotonergic synapseSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
neuron projectionSodium-dependent serotonin transporterHomo sapiens (human)
nucleoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
cytoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2BHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID625295Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in Pfizer data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID679793TP_TRANSPORTER: Western blot, primary hepatocytes1991Molecular carcinogenesis, , Volume: 4, Issue:6
Regulation of 2-acetylaminofluorene-and 3-methylcholanthrene--mediated induction of multidrug resistance and cytochrome P450IA gene family expression in primary hepatocyte cultures and rat liver.
AID681385TP_TRANSPORTER: RT-PCR in HK-2 cell2002Toxicology and applied pharmacology, Sep-01, Volume: 183, Issue:2
Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line.
AID681491TP_TRANSPORTER: RT-PCR in vivo Wistar rat, liver1995Molecular carcinogenesis, Jul, Volume: 13, Issue:3
Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy.
AID678990TP_TRANSPORTER: Western blot, primary hepatocytes2001Toxicology letters, Mar-31, Volume: 120, Issue:1-3
Up-regulation of transporters of the MRP family by drugs and toxins.
AID340123Toxicity in Salmonella Typhimurium TA1538 assessed as induction of mutagenicity using cytochrome P450 chemical model after 44 hrs by Ames test2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Oxidative transformation of 2-acetylaminofluorene by a chemical model for cytochrome P450: A water-insoluble porphyrin and tert-butyl hydroperoxide.
AID565860Binding affinity to DNA assessed as DNA adduct formation2010Journal of natural products, Dec-27, Volume: 73, Issue:12
Identification of a reduction product of aristolochic acid: implications for the metabolic activation of carcinogenic aristolochic acid.
AID168107Compound was tested for carcinogenic activity on mixed data after various routes administration of the compound; + denotes four or five active sites1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines.
AID680927TP_TRANSPORTER: RNase protection assay in embryonic 293 cells2002Oncogene, Mar-27, Volume: 21, Issue:13
Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling.
AID678991TP_TRANSPORTER: Northern blot from primary hepatocytes2001Toxicology letters, Mar-31, Volume: 120, Issue:1-3
Up-regulation of transporters of the MRP family by drugs and toxins.
AID168081Compound was tested for carcinogenic activity on ear duct after various routes administration of the compound; + denotes carcinogenic activity.1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines.
AID168094Compound was tested for carcinogenic activity on liver after various routes administration of the compound; + denotes carcinogenic activity.1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines.
AID679671TP_TRANSPORTER: Northern blot from HepG2 cells2001Toxicology letters, Mar-31, Volume: 120, Issue:1-3
Up-regulation of transporters of the MRP family by drugs and toxins.
AID680876TP_TRANSPORTER: RT-PCR in vivo Wistar rat, liver1995Molecular carcinogenesis, Jul, Volume: 13, Issue:3
Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy.
AID679656TP_TRANSPORTER: RT-PCR in HepG2 cells2001Toxicology letters, Mar-31, Volume: 120, Issue:1-3
Up-regulation of transporters of the MRP family by drugs and toxins.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID167946Compound was tested for carcinogenic activity on breast after various routes administration of the compound; + denotes carcinogenic activity.1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines.
AID681059TP_TRANSPORTER: Northern blot from primary hepatocytes1996Carcinogenesis, May, Volume: 17, Issue:5
Differential regulation of mdr genes in response to 2-acetylaminofluorene treatment in cultured rat and human hepatocytes.
AID680928TP_TRANSPORTER: Northern blot from primary hepatocytes1996Carcinogenesis, May, Volume: 17, Issue:5
Differential regulation of mdr genes in response to 2-acetylaminofluorene treatment in cultured rat and human hepatocytes.
AID681487TP_TRANSPORTER: Western in vivo Wistar rat, liver1995Molecular carcinogenesis, Jul, Volume: 13, Issue:3
Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy.
AID168252Compound was tested for carcinogenic activity on other sites after various routes administration of the compound; + denotes carcinogenic activity.1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines.
AID681337TP_TRANSPORTER: Western blot, HK-2 cells2002Toxicology and applied pharmacology, Sep-01, Volume: 183, Issue:2
Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line.
AID680926TP_TRANSPORTER: RNase protection assay in HepG2 cells2002Oncogene, Mar-27, Volume: 21, Issue:13
Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling.
AID167935Compound was tested for carcinogenic activity on all sites after various routes administration of the compound; + denotes carcinogenic activity.1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines.
AID682059TP_TRANSPORTER: RT-PCR in HepG2 cells2001Toxicology letters, Mar-31, Volume: 120, Issue:1-3
Up-regulation of transporters of the MRP family by drugs and toxins.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,228)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901409 (63.24)18.7374
1990's473 (21.23)18.2507
2000's238 (10.68)29.6817
2010's97 (4.35)24.3611
2020's11 (0.49)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.10

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.10 (24.57)
Research Supply Index7.76 (2.92)
Research Growth Index4.11 (4.65)
Search Engine Demand Index35.22 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.10)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews64 (2.72%)6.00%
Case Studies1 (0.04%)4.05%
Observational0 (0.00%)0.25%
Other2,287 (97.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]